CoChat

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

Open access

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.

Abstract

Several promising plasma biomarkers for Alzheimer's disease have been recently developed, but their neuropathological correlates have not yet been fully determined. To investigate and compare independent associations between multiple plasma biomarkers (p‐tau181, p‐tau217, p‐tau231, Aβ42/40, GFAP, and NfL) and neuropathologic measures of amyloid and tau, we included 105 participants from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) with antemortem plasma samples and a postmortem neuropathological exam, 48 of whom had longitudinal p‐tau217 and p‐tau181. When simultaneously including plaque and tangle loads, the Aβ42/40 ratio and p‐tau231 were only associated with plaques (ρ Aβ42/40 [95%CI] = −0.53[−0.65, −0.35], ρ p‐tau231 [95%CI] = 0.28[0.10, 0.43]), GFAP was only associated with tangles (ρ GFAP [95%CI] = 0.39[0.17, 0.57]), and p‐tau217 and p‐tau181 were associated with both plaques (ρ p‐tau217 [95%CI] = 0.40[0.21, 0.56], ρ p‐tau181 [95%CI] = 0.36[0.15, 0.50]) and tangles (ρ p‐tau217 [95%CI] = 0.52[0.34, 0.66]; ρ p‐tau181 [95%CI] = 0.36[0.17, 0.52]). A model combining p‐tau217 and the Aβ42/40 ratio showed the highest accuracy for predicting the presence of Alzheimer's disease neuropathological change (ADNC, AUC[95%CI] = 0.89[0.82, 0.96]) and plaque load ( R 2 = 0.55), while p‐tau217 alone was optimal for predicting tangle load ( R 2 = 0.45). Our results suggest that high‐performing assays of plasma p‐tau217 and Aβ42/40 might be an optimal combination to assess Alzheimer's‐related pathology in vivo .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202217123

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Associations between plasma biomarkers and amyloid plaque or neurofibrillary tau tangle loads Black lines represent the association between plasma biomarkers and amyloid plaque (A) and tau tangle (B) loads after adjusting for covariates (age, sex, and time between blood sampling and death), but dots represent raw data. Shadowed area represents the 95%CI. Plaque and tangle loads were measured on a semi‐quantitative scale from 0 to 3 using the CERAD (Mirra et al, 1991) templates in five different regions that were added up to a total score ranging from 0 to 15. Datapoints are colored based on the ADNC classification. Standardized Spearman's ρ and P‐values of the association between plasma biomarkers and a load of amyloid plaques or tau tangles are shown in the plot. Aβ, amyloid‐β; ADNC, Alzheimer's disease neuropathologic change; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; CI, confidence interval; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p‐tau, phosphorylated tau.
Figure 1 Associations between plasma biomarkers and amyloid plaque or neurofibrillary tau tangle loads Black lines represent the association between plasma biomarkers and amyloid plaque (A) and tau tangle (B) loads after adjusting for covariates (age, sex, and time between blood sampling and death), but dots represent raw data. Shadowed area represents the 95%CI. Plaque and tangle loads were measured on a semi‐quantitative scale from 0 to 3 using the CERAD (Mirra et al, 1991) templates in five different regions that were added up to a total score ranging from 0 to 15. Datapoints are colored based on the ADNC classification. Standardized Spearman's ρ and P‐values of the association between plasma biomarkers and a load of amyloid plaques or tau tangles are shown in the plot. Aβ, amyloid‐β; ADNC, Alzheimer's disease neuropathologic change; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; CI, confidence interval; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p‐tau, phosphorylated tau.CC BY · PubMed Central
Figure 2 Specific associations between plasma levels and both amyloid plaque and tau tangle loads Bars represent the partial Spearman's ρ of amyloid plaque load (blue) and tau tangle load (orange) on plasma levels after adjusting for the other pathology load. In separate models, each biomarker was used as a dependent variable and either amyloid load or tau load as independent variables adjusting for the other pathology measure. We also adjusted for age, sex, and time between blood sampling and death. Numbers inside the bars represent partial Spearman's ρ and numbers above the bars represent the percentual partial Spearman's ρ over the sum of the partial Spearman's ρ of the two pathologies' (%partial ρ = 100*partial ρ/[partial ρplaque + partial ρtangle]). Aβ, amyloid‐β; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p‐tau, phosphorylated tau.
Figure 2 Specific associations between plasma levels and both amyloid plaque and tau tangle loads Bars represent the partial Spearman's ρ of amyloid plaque load (blue) and tau tangle load (orange) on plasma levels after adjusting for the other pathology load. In separate models, each biomarker was used as a dependent variable and either amyloid load or tau load as independent variables adjusting for the other pathology measure. We also adjusted for age, sex, and time between blood sampling and death. Numbers inside the bars represent partial Spearman's ρ and numbers above the bars represent the percentual partial Spearman's ρ over the sum of the partial Spearman's ρ of the two pathologies' (%partial ρ = 100*partial ρ/[partial ρplaque + partial ρtangle]). Aβ, amyloid‐β; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p‐tau, phosphorylated tau.CC BY · PubMed Central
Figure 3 Plasma levels by ADNC classification Groups were compared using a pairwise Wilcoxon test as a post hoc comparison after testing tendency using a Kruskal–Wallis test. Post hoc comparisons were only performed between consecutive groups (n comp = 3). Central band of the boxplot represents the median of the group, the lower and upper hinges correspond to the first and third quartiles, and the whiskers represent the maximum/minimum value or the 1.5 IQR from the hinge, whatever is lower. ***P ≤ 0.001; **P ≤ 0.010; *P ≤ 0.050. Aβ, amyloid‐β; ADNC, Alzheimer's disease neuropathologic change; CI, confidence interval; GFAP, glial fibrillary acidic protein; IQR, interquartile range; NfL, neurofilament light; p‐tau, phosphorylated tau.
Figure 3 Plasma levels by ADNC classification Groups were compared using a pairwise Wilcoxon test as a post hoc comparison after testing tendency using a Kruskal–Wallis test. Post hoc comparisons were only performed between consecutive groups (n comp = 3). Central band of the boxplot represents the median of the group, the lower and upper hinges correspond to the first and third quartiles, and the whiskers represent the maximum/minimum value or the 1.5 IQR from the hinge, whatever is lower. ***P ≤ 0.001; **P ≤ 0.010; *P ≤ 0.050. Aβ, amyloid‐β; ADNC, Alzheimer's disease neuropathologic change; CI, confidence interval; GFAP, glial fibrillary acidic protein; IQR, interquartile range; NfL, neurofilament light; p‐tau, phosphorylated tau.CC BY · PubMed Central
Figure 4 Plasma biomarkers for predicting neuropathological scales' classification ROC curves for all models are shown in the left column and the correspondent AUC and 95% CI are shown in the right column. Models for all individual plasma biomarkers and the parsimonious (when available) model are shown. All models included: age, sex, and time between blood sampling and death as covariates. The parsimonious model for ADNC and CERAD included p‐tau217 and Aβ42/40 as predictors. The basic model includes only covariates. ADNC was dichotomized as negative (none/low) or positive (intermediate/high). CERAD was dichotomized as negative (low/sparse) or positive (moderate/frequent). Braak stages were dichotomized as negative (0–IV) or positive (V–VI). The individual biomarker with the best performance is shown as a solid bold line. Dashed lines represent individual biomarkers with significant (P < 0.05) lower AUC than the best individual biomarker (p‐tau217 in all cases). Other models with solid lines represent AUC equivalent to that of the best individual biomarker. Aβ, amyloid‐β; ADNC, Alzheimer's disease neuropathologic change; AUC, area under the curve; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; CI, confidence interval; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p‐tau, phosphorylated tau; ROC, receiver‐operating characteristic.
Figure 4 Plasma biomarkers for predicting neuropathological scales' classification ROC curves for all models are shown in the left column and the correspondent AUC and 95% CI are shown in the right column. Models for all individual plasma biomarkers and the parsimonious (when available) model are shown. All models included: age, sex, and time between blood sampling and death as covariates. The parsimonious model for ADNC and CERAD included p‐tau217 and Aβ42/40 as predictors. The basic model includes only covariates. ADNC was dichotomized as negative (none/low) or positive (intermediate/high). CERAD was dichotomized as negative (low/sparse) or positive (moderate/frequent). Braak stages were dichotomized as negative (0–IV) or positive (V–VI). The individual biomarker with the best performance is shown as a solid bold line. Dashed lines represent individual biomarkers with significant (P < 0.05) lower AUC than the best individual biomarker (p‐tau217 in all cases). Other models with solid lines represent AUC equivalent to that of the best individual biomarker. Aβ, amyloid‐β; ADNC, Alzheimer's disease neuropathologic change; AUC, area under the curve; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; CI, confidence interval; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p‐tau, phosphorylated tau; ROC, receiver‐operating characteristic.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 205

Metadata

Authors
Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., & Hansson, O.
Affiliations
  • Lund University (SE)
  • King's College London (GB)
  • Banner Sun Health Research Institute (US)
  • University of Arizona (US)
  • Sahlgrenska University Hospital (SE)
Corresponding author
  • Salvadó, Gemma
  • Hansson, Oskar
Venue
EMBO Molecular Medicine
Published
2023-03-13
Volume
15
Issue
5
Pages
e17123-e17123
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W4324019853
Cited by
205
References
71
Citations by year
2026: 52 · 2025: 70 · 2024: 62 · 2023: 20
FWCI
35.94
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Lund University Publications (Lund University) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
Funders
  • AD Strategic Fund and Alzheimer's Association (ADSF‐21‐831376‐C, ADSF‐21‐831381‐C, ADSF‐21‐831377‐C)
  • ALF‐agreement (ALFGBG‐715986, ALFGBG‐965240)
  • Alzheimer Drug Discovery Foundation (201809‐2016862, RDAPB‐201809‐2016615)
  • Alzheimer's Association 2021 Zenith Award (ZEN‐21‐848495)
  • Bluefield Project
  • Erling Persson Family Foundation
  • European Research Council (681712, 101053962)
  • European Union Joint Program for Neurodegenerative Disorders (JPND2019‐466‐236)
  • European Union Joint Programme—Neurodegenerative Disease Research (JPND2021‐00694)
  • Greta och Johan Kocks stiftelser
  • Hj#x00E4;rnfonden, Sweden (FO2017‐0243, ALZ2022‐0006)
  • Knut och Alice Wallenbergs Stiftelse (2017‐0383)
  • Konnung Gustaf och Drottning Victorias Frimurarestiftelse
  • Marianne and Marcus Wallenberg Foundation (2015.0125)
  • Marie Sklodowska‐Curie (101061836, 860197)
  • National Institute of Health, USA (1R01AG068398‐01)
  • Olav Thon Foundation
  • Parkinson Foundation of Sweden (1280/20)
  • Skane University Hospital Foundation (2020‐O000028)
  • Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022‐0270)
  • Strategic Research Area MultiPark
  • Swedish Alzheimer Foundation (AF‐939932, AF‐930351, AF‐939721, AF‐968270)
  • Swedish Brain Foundation (FO2021‐0293)
  • Swedish Federal Government (2018‐Projekt0279)
  • Swedish Research Council (2016‐00906, 2018‐02532, 2017‐00915)
  • Swedish State Support for Clinical Research (ALFGBG‐71320)
  • UK Dementia Research Institute at UCL (UKDRI‐1003)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
Alzheimer's disease, plasma biomarkers, postmortem neuropathology, amyloid plaques, tau tangles, phosphorylated tau, p-tau217, p-tau181, p-tau231, amyloid-beta 42/40 ratio, glial fibrillary acidic protein, neurofilament light chain, biomarker prediction
MeSH terms
Neuropathology, Alzheimer Disease, Autopsy, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. https://app.cochat.ai/papers/10.15252/emmm.202217123
The paper
Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., & Hansson, O. (2023). Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202217123

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.